Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.
Body mass index (BMI) of 18 to 32 kg/m²;
Serum HBsAg<100 IU/mL;
HBV DNA<20 IU/mL;
HBeAg-negative.
A history of allergy, or who are suspected by the researcher to be allergic to the active ingredient of the drug under study or its excipients;
Use of immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before enrollment, or vaccination of live attenuated vaccine within 1 month before enrollment;
Acute infection within 2 weeks before enrollment which requires intravenous antibiotic treatment, or existing infection which requires anti-infection treatment when enrollment;
Confirmed or suspected decompensated cirrhosis;
The Second Affiliated Hospital of Chongqing Medical University
Lead sponsor
First Affiliated Hospital of Chongqing Medical University
Collaborator
Three Gorges Hospital of Chongqing University
Collaborator
Guizhou Provincial People's Hospital
Collaborator